GLP1R and type 2 diabetes mellitus: The GLP-1 RAs approved for type 2 diabetes before 2021 included dulaglutide (Trulicity), liraglutide (Saxenda and Victoza), exenatide (Bydueron and Byetta), and semaglutide (Ozempic and Rybelsus); and in 2022, a dual glucose-dependent insulinotropic polypeptide and GLP-1 RA, tirzepatide (Mounjaro).